ImpriMed
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
$10MSeries A2 bridge
LeadLI
LB Investment
Activity from announced rounds
Activity in this selectionOct 16, 2026 · Jul 19, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $146M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionPoint2 Technology
Develops RF-based interconnect technology for AI data-center and automotive networking
$136MSeries B
Role not disclosed